Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of “Buy” from Brokerages

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have been assigned a consensus recommendation of “Buy” from the eight research firms that are currently covering the firm, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $6.88.

Several research analysts have weighed in on the company. Piper Sandler assumed coverage on Taysha Gene Therapies in a research report on Tuesday, April 9th. They set an “overweight” rating and a $9.00 price target on the stock. Chardan Capital boosted their price target on Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, March 21st. JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a report on Wednesday, March 20th. Needham & Company LLC reissued a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, April 11th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, April 18th.

Institutional Trading of Taysha Gene Therapies

Several institutional investors and hedge funds have recently modified their holdings of TSHA. FMR LLC lifted its position in shares of Taysha Gene Therapies by 2,035.0% during the 3rd quarter. FMR LLC now owns 24,527,801 shares of the company’s stock worth $77,508,000 after buying an additional 23,378,974 shares during the last quarter. RA Capital Management L.P. bought a new stake in shares of Taysha Gene Therapies during the 3rd quarter worth $58,373,000. RTW Investments LP bought a new stake in shares of Taysha Gene Therapies during the 3rd quarter worth $53,382,000. Acuta Capital Partners LLC bought a new stake in shares of Taysha Gene Therapies during the 3rd quarter worth $12,096,000. Finally, Vanguard Group Inc. lifted its position in shares of Taysha Gene Therapies by 235.2% during the 3rd quarter. Vanguard Group Inc. now owns 5,327,864 shares of the company’s stock worth $16,836,000 after buying an additional 3,738,616 shares during the last quarter. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Stock Up 3.9 %

Shares of Taysha Gene Therapies stock opened at $2.39 on Friday. The business’s 50 day simple moving average is $2.64 and its 200 day simple moving average is $2.09. Taysha Gene Therapies has a 52-week low of $0.50 and a 52-week high of $3.89. The firm has a market cap of $446.98 million, a PE ratio of -3.57 and a beta of 0.29. The company has a debt-to-equity ratio of 0.54, a quick ratio of 4.08 and a current ratio of 4.08.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Tuesday, March 19th. The company reported $0.35 earnings per share (EPS) for the quarter. The firm had revenue of $3.60 million during the quarter, compared to analyst estimates of $4.75 million. On average, analysts predict that Taysha Gene Therapies will post -0.39 earnings per share for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.